Correlation of anti-tumor adaptive immunity with clinical response in a phase II “Window” trial of neoadjuvant cetuximab in patients with resectable stage III-IV head and neck squamous carcinoma (HNSCC).
Robert L. Ferris(University of Pittsburgh), Julie E. Bauman(George Washington University), Dwight E. Heron(Bon Secours Mercy Health), Umamaheswar Duvvuri(City University of New York), D.A. Clump(UPMC Hillman Cancer Center), Fernando Concha‐Benavente(UPMC Hillman Cancer Center), James Ohr(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), Raghvendra M. Srivastava(University of Pittsburgh), Jonas T. Johnson(University of Pittsburgh), Sumita Trivedi, William E. Gooding(UPMC Hillman Cancer Center)
Cited by 9
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688